Acadian Asset Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Acadian Asset Management’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-479	Closed	-$90K	–	2106
2019 Q3	$90K	Sell	479 -217	-31%	-$49.8K	﹤0.01%	1510
2019 Q2	$187K	Hold	696	–	–	﹤0.01%	1240
2019 Q1	$263K	Buy	696 +130	+23%	+$43.6K	﹤0.01%	1287
2018 Q4	$210K	Hold	566	–	–	﹤0.01%	1104
2018 Q3	$244K	Hold	566	–	–	﹤0.01%	1044
2018 Q2	$205K	Buy	566 +98	+21%	+$46.1K	﹤0.01%	1080
2018 Q1	$214K	Buy	468 +226	+93%	+$112K	﹤0.01%	1041
2017 Q4	$140K	Buy	+242	New	+$159K	﹤0.01%	1026
2016 Q4	–	Sell	-13	Closed	-$13K	–	1800
2016 Q3	$13K	Buy	+13	New	+$16.4K	﹤0.01%	1208
2016 Q2	–	Sell	-4	Closed	-$5K	–	1562
2016 Q1	$5K	Hold	4	–	–	﹤0.01%	1279
2015 Q4	$6K	Buy	4 +3	+300%	+$3.91K	﹤0.01%	1290
2015 Q3	$2K	Buy	+1	New	+$1.93K	﹤0.01%	1263

Other funds holding FRTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management's FRTX Position: Q4 2019 in Review

Acadian Asset Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2019, closing a stake of 479 shares — an estimated $90K sold.

Acadian Asset Management first reported a position in FRTX in Q3 2015 and held it in 12 quarters. The position peaked at $263K in Q1 2019. 12 funds tracked by Wall St. Rank hold FRTX as of Q4 2019.

Acadian Asset Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Acadian Asset Management sold 479 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $90K.
Acadian Asset Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q3 2015 and held it in 12 quarters.
Acadian Asset Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $263K in Q1 2019.
12 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Acadian Asset Management's 13F filing for Q4 2019, filed 6 Feb 2020.